6
Oct
2026

Kemwell Biopharma

Exhibitor at CPHI Milan 2026 stand 12C64, Contract Manufacturing & Services
About Us

Kemwell Biopharma is a leading biologics CDMO based in Bengaluru, India, offering end-to-end services from cell line and process development to cGMP clinical and commercial manufacturing. Its 15,000 sq. m facility, built with Boehringer Ingelheim, includes 5,000 L bioreactor capacity and sterile fill-finish for vials and PFS. In October 2025, Kemwell completed a U.S. FDA PAI for an injectable drug product, reinforcing its global quality standards and trusted partnerships since 1980.Kemwell specializes in mammalian cell-based biologics, including mAbs, complex proteins and biosimilars.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    India
  • On CPHI since:
    2021
  • Certificates:
    3
  • Employees:
    250 - 499
Company types
CMO/CDMO
Primary activities
Contract Manufacturer
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 12C64, Contract Manufacturing & Services

Products Featured at CPHI Milan 2026

  • Kemwell Biopharma

    Product Kemwell Biopharma

    SERVICES Kemwell provides integrated development and manufacturing services for companies that require one-stop solution for mammalian cell-culture based protein therapeutics The team is experienced to undertake end-to-end activities right from cell line development till cGMP clinical and commercial manufa...
  • Kemwell Biopharma - Analytical Development

    Product Kemwell Biopharma - Analytical Development

    - Method development, qualification and validation services. - Platform methodologies - Offers as part of integrated or standalone service - Tests performed in-house for in-process and release, including in vitro bioassay and sterility, endotoxin.
  • Kemwell Biopharma - Formulation Development

    Product Kemwell Biopharma - Formulation Development

    - Pre-formulation Studies - Formulation Screening Studies - Lyophilization Cycle Development
  • Kemwell Biopharma - Process Development

    Product Kemwell Biopharma - Process Development

    Process Development - AMBR®250, Shake flasks, 5L, 10L (glass bioreactors), 50L (SUB), 80L (SS) – adaptable to support perfusion systems - Non-GLP and GLP tox material generation - Well characterized and geometrically similar bioreactors in pilot and GMP facility - Integrated with analytical development and...
  • Why Kemwell Services ?

    Product Why Kemwell Services ?

    -Integrated Service Provider – Drug Substance and Drug Product -Diverse experience – monoclonal antibodies, complex fusion proteins, recombinant proteins and bispecific antibodies -First CDMO in India licensed to manufacture commercial DS -4 years accomplishments – 7 projects in process development, 6 clin...

Kemwell Biopharma Resources (1)